Ignite Creation Date:
2024-10-25 @ 7:57 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06601465
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-06
Brief Title:
COgnitioN with VERiciGuat Evaluation in Heart Failure
Sponsor:
None
Organization:
None
Study Overview
Official Title:
CONVERGE-HF COgnitioN with VERiciGuat Evaluation in Heart Failure
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CONVERGE-HF
Brief Summary:
CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure 6 months and mild-to-moderate cognitive impairment
Detailed Description:
CONVERGE-HF is a randomized open label phase IIb trial evaluating the effect of sGC stimulator Vericiguat versus standard of care on imaging markers and blood markers of cerebral and coronary small vessel diseases function status cognitive status quality of life and clinical events in patients with heart failure and mild-to-moderate cognitive impairment Patients will be randomized and allocated to either vericiguat or standard of care for 26 weeks including the greater than 4 weeks timeframe for the uptitrations to the target dose
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None